Effectiveness of 8- or 12-weeks of ledipasvir and sofosbuvir in real-world treatment-naïve, genotype 1 hepatitis C infected patients

Alimentary Pharmacology & Therapeutics ◽

10.1111/apt.14204 ◽

2017 ◽

Vol 46 (5) ◽

pp. 540-548 ◽

Author(s):

M. P. Curry ◽

E. B. Tapper ◽

B. Bacon ◽

D. Dieterich ◽

S. L. Flamm ◽

...

Keyword(s):

Hepatitis C ◽

Treatment Naïve

Download Full-text

Direct antiviral agents for treatment-naïve patients with genotype 1 hepatitis C: A statistical model for comparing outcomes between real world and clinical trials

Digestive and Liver Disease ◽

10.1016/j.dld.2015.06.012 ◽

2015 ◽

Vol 47 (11) ◽

pp. 988-989

Author(s):

Andrea Messori ◽

Maurizia R. Brunetto ◽

Andrea De Luca ◽

Anna Linda Zignego

Keyword(s):

Clinical Trials ◽

Hepatitis C ◽

Statistical Model ◽

Antiviral Agents ◽

Treatment Naïve ◽

Direct Antiviral Agents

Download Full-text

EFFECTIVENESS OF 8 OR 12 WEEK LDV/SOF IN TREATMENT-NAÏVE PATIENTS WITH NON-CIRRHOTIC, GENOTYPE 1 HEPATITIS C: REAL-WORLD EXPERIENCE FROM THE TRIO NETWORK

Value in Health ◽

10.1016/j.jval.2016.03.992 ◽

2016 ◽

Vol 19 (3) ◽

pp. A313 ◽

Author(s):

M. Curry ◽

B. Bacon ◽

D. Dieterich ◽

S. Flamm ◽

L. Guest ◽

...

Keyword(s):

Hepatitis C ◽

Treatment Naïve

Download Full-text

Faculty Opinions recommendation of Real-world effectiveness of ledipasvir/sofosbuvir in 4,365 treatment-naive, genotype 1 hepatitis C-infected patients.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.726313807.793517680 ◽

2016 ◽

Author(s):

Doug Dieterich ◽

Dost Sarpel

Keyword(s):

Hepatitis C ◽

Treatment Naïve

Download Full-text

Real-world effectiveness of ledipasvir/sofosbuvir in 4,365 treatment-naive, genotype 1 hepatitis C-infected patients

10.1002/hep.28625 ◽

2016 ◽

Vol 64 (2) ◽

pp. 405-414 ◽

Author(s):

Lisa I. Backus ◽

Pamela S. Belperio ◽

Troy A. Shahoumian ◽

Timothy P. Loomis ◽

Larry A. Mole

Keyword(s):

Hepatitis C ◽

Treatment Naïve

Download Full-text

Su1431 Use of 8 Weeks Regimen of Sofosbuvir And Ledipasvir Without Ribavirin, In Non-Cirrhotic Treatment-Naïve Hepatitis C Genotype 1 Patients With Less Than 6 Million IU/ml Viral Load: Real-World Experience

Gastroenterology ◽

10.1016/s0016-5085(16)33708-8 ◽

2016 ◽

Vol 150 (4) ◽

pp. S1098

Author(s):

Kamran Qureshi ◽

John Regester ◽

Joshua Halladay ◽

Paul Urick

Keyword(s):

Hepatitis C ◽

Treatment Naïve

Download Full-text

Eight-week ledipasvir/sofosbuvir in non-cirrhotic, treatment-naïve hepatitis C genotype-1 patients with hepatitis C virus-RNA < 6 million: Single center, real world effectiveness and safety

World Journal of Gastroenterology ◽

10.3748/wjg.v23.i26.4759 ◽

2017 ◽

Vol 23 (26) ◽

pp. 4759 ◽

Author(s):

Nyan L Latt ◽

Beshoy T Yanny ◽

Derenik Gharibian ◽

Rita Gevorkyan ◽

Amandeep K Sahota

Keyword(s):

Hepatitis C Virus ◽

Hepatitis C ◽

Single Center ◽

Hepatitis C Virus Rna ◽

Virus Rna ◽

Treatment Naïve

Download Full-text

Treatment of chronic hepatitis C Genotype 1 (G1) infection with boceprevir (Victrelis®) in the German real-life setting: First results for treatment-naïve patients from the Novus observational study

Zeitschrift für Gastroenterologie ◽

10.1055/s-0033-1352957 ◽

2013 ◽

Vol 51 (08) ◽

Author(s):

P Buggisch ◽

H Löhr ◽

G Teuber ◽

H Steffens ◽

M Kraus ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C ◽

Observational Study ◽

Chronic Hepatitis C ◽

Real Life ◽

Real Life Setting ◽

First Results ◽

Treatment Naïve

Download Full-text

High real-world effectiveness of elbasvir/grazoprevir (EBR/GZR) in PWID on opioid substitution therapy with HCV genotype 1 (GT1) infection: results from the German Hepatitis C Registry (DHC-R)

10.1055/s-0039-1695339 ◽

2019 ◽

Author(s):

S Christensen ◽

A Stoehr ◽

M Cornberg ◽

H Klinker ◽

R Heyne ◽

...

Keyword(s):

Hepatitis C ◽

Substitution Therapy ◽

Opioid Substitution Therapy ◽

Hcv Genotype ◽

Hcv Genotype 1 ◽

Opioid Substitution

Download Full-text

Faculty of 1000 evaluation for Randomised clinical trial: pre-dosing with taribavirin before starting pegylated interferon vs. standard combination regimen in treatment-naïve patients with chronic hepatitis C genotype 1.

F1000 - Post-publication peer review of the biomedical literature ◽

10.3410/f.717965604.793466618 ◽

2012 ◽

Author(s):

Alex Thompson

Keyword(s):

Clinical Trial ◽

Chronic Hepatitis ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Pegylated Interferon ◽

Randomised Clinical Trial ◽

Combination Regimen ◽

Treatment Naïve

Download Full-text

Faculty Opinions recommendation of Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718020296.793478787 ◽

2013 ◽

Author(s):

Arthur Kim

Keyword(s):

Hepatitis C ◽

Phase 2 ◽

Hepatitis C Infection ◽

Multicentre Phase ◽

Phase 2 Trial ◽

Treatment Naïve ◽

Peginterferon Alfa ◽

Download Full-text